Ocumension Therapeutics announced that, the phase II clinical trial of OT-202 (tyrosine kinase inhibitor), a first-in-class new drug self-developed by the Company for the treatment of dry eye, has successfully completed the unblinding with all related data collected, which marks OT-202 has achieved the primary clinical endpoint of phase II clinical trial, i.e., the group that received the treatment with the drug exhibited greater improvement in corneal staining scores from baseline compared to the placebo group by day 56. The drug has also demonstrated positive results in safety and efficacy. The Company expects to launch phase III clinical trial of OT-202 in the near future.

OT-202 (tyroine kinase inhibitor) is a first-in-class New drug self-developed by the company for the treatment of moderate to severe dry eye. The mechanism of action of OT-202 is that the dualtargeted inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor-2 achieves a synergistic effect in the treatment of dry eye diseases and inhibits the inflammatory response. OT-202 demonstrated good safety and tolerability profile in healthy adult subjects in the phase I clinical trial successfully completed in February 2023.

The phase II clinical trial of OT -202, which was launched in February 2023 and designed to be a randomized, double-masked, placebo-controlled clinical trial on the safety and efficacy of the drug, has completed the enrollment of a total of 213 patients for the phase II clinical trial in China in November 2023.